Abbott Laboratories Pakistan Ltd
Abbott Laboratories Pakistan Ltd operates in Pharmaceuticals.
Abbott Laboratories Pakistan Ltd (ABOT) - Net Assets
Latest net assets as of June 2024: PKRs20.54 Billion PKR
Based on the latest financial reports, Abbott Laboratories Pakistan Ltd (ABOT) has net assets worth PKRs20.54 Billion PKR as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (PKRs35.80 Billion) and total liabilities (PKRs15.26 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | PKRs20.54 Billion |
| % of Total Assets | 57.37% |
| Annual Growth Rate | 3.24% |
| 5-Year Change | 36.38% |
| 10-Year Change | N/A |
| Growth Volatility | 7.81 |
Abbott Laboratories Pakistan Ltd - Net Assets Trend (2016–2023)
This chart illustrates how Abbott Laboratories Pakistan Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Abbott Laboratories Pakistan Ltd (2016–2023)
The table below shows the annual net assets of Abbott Laboratories Pakistan Ltd from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | PKRs18.24 Billion | +6.61% |
| 2022-12-31 | PKRs17.11 Billion | -1.43% |
| 2021-12-31 | PKRs17.35 Billion | +11.32% |
| 2020-12-31 | PKRs15.59 Billion | +16.59% |
| 2019-12-31 | PKRs13.37 Billion | +1.04% |
| 2018-12-31 | PKRs13.24 Billion | -7.81% |
| 2017-12-31 | PKRs14.36 Billion | -1.63% |
| 2016-12-31 | PKRs14.59 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Abbott Laboratories Pakistan Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1048275900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | PKRs10.48 Billion | 57.48% |
| Other Components | PKRs7.75 Billion | 42.52% |
| Total Equity | PKRs18.24 Billion | 100.00% |
Abbott Laboratories Pakistan Ltd Competitors by Market Cap
The table below lists competitors of Abbott Laboratories Pakistan Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
H.W.A. AG - Dusseldorf Stock Exchang
DU:H9W
|
$31.06K |
|
CEA Industries Inc. Warrant
NASDAQ:CEADW
|
$31.06K |
|
TEKA4F
SA:TEKA4F
|
$31.06K |
|
TELKOM SA SOC
MU:TZL1
|
$31.06K |
|
WISHBONE GOLD PLC LS-001
F:7N6
|
$31.03K |
|
C2E Energy Inc
PINK:OOGI
|
$30.99K |
|
JOPA3F
SA:JOPA3F
|
$30.98K |
|
James Fisher and Sons PLC
LSE:FSJ
|
$30.95K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abbott Laboratories Pakistan Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 17,106,029,000 to 18,237,346,000, a change of 1,131,317,000 (6.6%).
- Net income of 261,777,000 contributed positively to equity growth.
- Dividend payments of 1,374,413,000 reduced retained earnings.
- Other factors increased equity by 2,243,953,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | PKRs261.78 Million | +1.44% |
| Dividends Paid | PKRs1.37 Billion | -7.54% |
| Other Changes | PKRs2.24 Billion | +12.3% |
| Total Change | PKRs- | 6.61% |
Book Value vs Market Value Analysis
This analysis compares Abbott Laboratories Pakistan Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.87x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 6.18x to 4.87x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | PKRs146.64 | PKRs906.68 | x |
| 2018-12-31 | PKRs135.19 | PKRs906.68 | x |
| 2019-12-31 | PKRs136.59 | PKRs906.68 | x |
| 2020-12-31 | PKRs159.25 | PKRs906.68 | x |
| 2021-12-31 | PKRs177.27 | PKRs906.68 | x |
| 2022-12-31 | PKRs174.73 | PKRs906.68 | x |
| 2023-12-31 | PKRs186.28 | PKRs906.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abbott Laboratories Pakistan Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.47%
- • Asset Turnover: 1.51x
- • Equity Multiplier: 2.01x
- Recent ROE (1.44%) is below the historical average (21.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 27.56% | 17.20% | 1.33x | 1.21x | PKRs2.56 Billion |
| 2017 | 29.29% | 16.12% | 1.36x | 1.34x | PKRs2.77 Billion |
| 2018 | 20.36% | 9.07% | 1.47x | 1.53x | PKRs1.37 Billion |
| 2019 | 9.72% | 4.31% | 1.45x | 1.55x | PKRs-37.35 Million |
| 2020 | 29.09% | 12.85% | 1.42x | 1.60x | PKRs2.98 Billion |
| 2021 | 34.38% | 14.02% | 1.49x | 1.65x | PKRs4.23 Billion |
| 2022 | 17.56% | 6.10% | 1.45x | 1.98x | PKRs1.29 Billion |
| 2023 | 1.44% | 0.47% | 1.51x | 2.01x | PKRs-1.56 Billion |
Industry Comparison
This section compares Abbott Laboratories Pakistan Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $19,223,187,000
- Average return on equity (ROE) among peers: 13.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abbott Laboratories Pakistan Ltd (ABOT) | PKRs20.54 Billion | 27.56% | 0.74x | $31.06K |
| AGP Ltd (AGP) | $12.36 Billion | 12.66% | 1.26x | $6.39K |
| The Searle Company Ltd (SEARL) | $26.09 Billion | 14.10% | 0.88x | $2.95K |